#DLBCL Archives - MediaMedic

The Prognostic Power of Tumor-Infiltrating B Cells in Diffuse Large B-cell Lymphoma: Implications for Precision Medicine

By Mourabit Halima 2024.03.18

Abstract: In the realm of diffuse large B-cell lymphoma (DLBCL) prognosis, the emergence of tumor-infiltrating B lymphocytes (TIL-Bs) as potent prognostic indicators has sparked a new wave of research and…

Dr. Alexander Fosså：Phase II waveLINE-004 Study of ROR1-ADC Treatment for R/R DLBCL

By Kenzy Nour 2024.01.11

On the 17th International Conference on Malignant Lymphoma (ICML), Dr. Alexander Fosså from Oslo University Hospital presented the results of the Zilovertamab vedotin (MK-2140) treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a Phase II open-label, waveLINE-004 study. Oncology Frontier interviewed Dr. Fosså at the conference.

Dr. Zhang Huilai Interpreted Multiple Studies by His Team at ICML 2023

By Mourabit Halima 2024.01.08

Editor's Note: The 17th International Conference on Malignant Lymphoma (ICML) took place from June 13 to 17, 2023, in Lugano, Switzerland. As the largest international conference in the field of…